Jim Palma, CEO at TargetCancer Foundation, shared a post on LinkedIn:
“To date, patients with over 65 different types of rare cancers have enrolled on the TargetCancer Foundation TRACK clinical trial. But we know that treatments will never be developed for each of those rare cancers. That’s why tissue agnostic therapies hold so much promise for patients with rare cancers, as they target biomarkers which might be present in any cancer.
To help drive a better understanding of this treatment approach, we have launched the newest resource in our suite of rare cancer patient education materials, Tissue-Agnostic Therapies in Rare Cancers.
You can view this resource and learn more by visiting the link.”
More posts featuring Jim Palma.